Rijhul Lahariya

Rijhul Lahariya

Auto-generated profile, based on publicly available information

Rijhul Lahariya

All India Institute of Medical Sciences, Patna, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
RLRijhul Lahariya
Rijhul Lahariya
GAGargee Anand
Gargee Anand
BKBandana Kumari
Bandana Kumari
KPKetan Priyadarshi
Ketan Priyadarshi

10 February 2026 in International Journal of Neuroscience
Verified
Journal Article
Closed access
RLRijhul Lahariya
Rijhul Lahariya
MSMainak Sinha
Mainak Sinha
BKBandana Kumari
Bandana Kumari
KSKeyush Venket Subramanian
Keyush Venket Subramanian
GAGargee Anand
Gargee Anand
Neurovascular unit (NVU) dysfunction is a central determinant of tissue injury, reperfusion failure, and long-term neurological outcomes after ischemic stroke. This review critically examines the cellular and molecular mechanisms underlying NVU disruption, with a particular focus on inflammation, oxidative stress, and blood-brain barrier (BBB) integrity, and evaluates emerging NVU-targeted therapeutic strategies. A focused narrative review synthesized studies on ischemic stroke-related NVU alterations, integrating cellular mechanisms, biomarkers, and phase-specific therapeutic strategies targeting BBB dysfunction, inflammation, oxidative stress, and neurorestoration. Acute ischemic injury induces endothelial tight-junction disruption, pericyte constriction and loss, astrocytic activation, and microglial-driven inflammation, resulting in BBB breakdown, impaired neurovascular coupling, and restricted microvascular reperfusion. These processes facilitate leukocyte infiltration, exacerbate secondary neuronal damage, and increase hemorrhagic transformation risk. Circulating and cerebrospinal fluid biomarkers, including MMP-9, GFAP, S100B, and pro-inflammatory cytokines, reflect NVU injury severity and correlate with functional outcomes. In the chronic phase, persistent BBB permeability, maladaptive VEGF signaling, and sustained low-grade inflammation contribute to white matter injury, impaired neuroplasticity, and post-stroke cognitive decline. Therapeutic strategies targeting NVU dysfunction include anti-inflammatory agents, COX-2 inhibitors, and NADPH oxidase inhibitors, alongside stem cell-based and extracellular vesicle-mediated approaches that promote vascular stabilization and repair. Neuroplasticity-enhancing interventions and nanoparticle-based drug delivery systems further support functional recovery. NVU dysfunction underlies both acute injury amplification and chronic recovery failure after stroke. Biomarker-guided, phase-specific therapeutic strategies targeting inflammation, oxidative stress, and BBB instability represent a promising framework for personalized stroke management.

17 August 2025 in Acta Clinica Belgica
Verified
Journal Article
Closed access
GAGargee Anand
Gargee Anand
RLRijhul Lahariya
Rijhul Lahariya
KPKetan Priyadarshi
Ketan Priyadarshi
ASAsim Sarfraz
Asim Sarfraz
To unmask the alarming prevalence, intricate antimicrobial resistance patterns, and consequential clinical outcomes of World Health Organization (WHO) priority pathogens causing device-associated infections in critical care settings - a frontier analysis of silent pandemic threatening modern healthcare. This groundbreaking retrospective study analysed data from 5,398 patients at risk for central line-associated bloodstream infections (CLABSI) and 15,416 patients for catheter-associated urinary tract infections (CAUTI) spanning 2021-2024. Microbial isolates were categorized according to WHO's priority pathogen classifications. Antimicrobial susceptibility profiles were comprehensively analysed using Clinical and Laboratory Standards Institute guidelines, with statistical analyses elucidating pathogen distribution dynamics, resistance mechanisms, and mortality correlations. Striking findings revealed WHO priority pathogens dominated the microbial landscape, constituting 76.47% of CLABSI and 82.14% of CAUTI isolates - with critical priority organisms overwhelmingly predominant (83.34% and 91.3%, respectively). Carbapenem-resistant Enterobacterales (CRE) emerged as the formidable leading threat (39.5% of CLABSI, 72.7% of CAUTI), while Carbapenem-resistant Acinetobacter baumannii (CRAB) demonstrated exceptional virulence with devastating mortality (93.33%). The study unveiled unprecedented levels of multidrug resistance, with most therapeutic options rendered ineffective; only colistin maintained universal efficacy against gram-negative isolates despite its concerning toxicity profile. Dramatic disparities in infection outcomes revealed CLABSI-associated mortality rates (71.79%) significantly eclipsed CAUTI (39.13%), establishing infection type as a critical independent predictor of survival. This landmark investigation exposes the crossroad between WHO priority pathogens and healthcare-associated infections, sounding an urgent alarm for global healthcare systems. Our findings provide crucial evidence-based guidance for recalibrating therapeutic approaches, optimizing antimicrobial selection, and prioritizing infection control measures in intensive care settings worldwide.

1 October 2025 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
RLRijhul Lahariya
Rijhul Lahariya
GAGargee Anand
Gargee Anand
BKBandana Kumari
Bandana Kumari


1 December 2025 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
GAGargee Anand
Gargee Anand
RLRijhul Lahariya
Rijhul Lahariya